Clinical trials: Thyroid Eye Disease
Graves' Disease
Post-Radioiodine Graves' Management: The PRAGMA-Study
Thyroid dysfunction following radioiodine for Graves' disease is common, potentially detrimental and avoidable. A variety of clinical strategies are employed in the post-radioiodine era util the patient is on a stable thyroid…
- Trial name
- PRAGMA (NCT01885533)
- Where
- 2 sites in United Kingdom
- Volunteers
- 803 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Type 1 Diabetes, Autoimmune Diseases
Additional Autoimmune Diseases With Type 1 Diabetes in Pediatrics at Diabetes Diagnosis and During Follow-up
This study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (T1D) diagnosis, and their incidence rate during follow-up, for children and adolescents.
- Conditions
- Type 1 Diabetes, Autoimmune Diseases, Hashimoto Disease, Graves Disease
- Trial name
- AADT1D (NCT04789993)
- Testing
- No intervention.
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Central Hospital, Nancy, France
Thyroid Eye Disease, TED
Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment
The purpose of this study was to evaluate the elasticity of the extraocular muscles in different stages of thyroid eye disease and to examine the correlation of MRI parameters (native T1 value and ECV) and elasticity for the…
- Trial name
- NCT07056114
- Testing
- The patients with active or inactive TED
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Tianjin Eye Hospital
Thyroid-Associated Ophthalmopathy
99Tc-MDP for Thyroid-Associated Ophthalmopathy
To investigate the efficacy，safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.
- Trial name
- NCT03948191
- Testing
- Methylprednisolone, 99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Dalian University
Thyroid Nodule (Benign), Graves Disease
Thyroid Artery Goitre Embolization Trial A Pilot Study Investigating Thyroid Artery Embolisation as a Treatment for Large Thyroid Nodules
Large non-cancerous thyroid nodules (lumps in the thyroid gland) can cause pressure or discomfort in the neck or cosmetic issues. The standard treatment options include radiofrequency ablation, radioactive iodine, and surgery.
- Conditions
- Thyroid Nodule (Benign), Graves Disease, Goitre
- Trial name
- TArGET (NCT07046546)
- Testing
- Thyroid artery embolization
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Royal Berkshire NHS Foundation Trust
Thyroid Eye Disease
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Thyroid eye disease (TED) is an autoimmune inflammation of the orbital tissues that develops in up to 50% of patients with Graves' disease.
- Trial name
- BetTeRTED (NCT02316691)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-1 (NCT07720635)
- Testing
- KHN939
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Benign Nontoxic and Toxic Goiter, Graves' Disease
rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter
The trials in this protocol deals with the effect of pretreatment with rhTSH on radioiodine treatment of thyroid size and function, in patients with nontoxic and toxic nodular goiter.
- Trial name
- NCT00145366
- Testing
- Recombinant human thyrotropin (Thyrogen)
- Where
- Denmark
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Graves Disease
Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects.
- Trial name
- NCT02993302
- Testing
- 1α-D3
- Volunteers
- 25 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Graves Ophthalmopathy
Glucocorticoids and Bone in Graves' Ophthalmopathy
Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid.
- Trial name
- NCT03122847
- Testing
- Methylprednisolone
- Where
- 2 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Torben Harsløf
Graves Disease, Graves Ophthalmopathy
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
Introduction: Graves disease (GD) is characterized by thyrotoxicosis and goiter, arising through circulating autoantibodies that bind to and stimulate the thyroid hormone receptor (TSHR).
- Conditions
- Graves Disease, Graves Ophthalmopathy, Graves' Ophthalmopathy Worsened
- Trial name
- NCT03066076
- Testing
- Antithyroid Drug, Total thyroidectomy
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Graves Ophthalmopathy, Graves Disease
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
The study is aimed at assessing IGF-1R-Abs in patients with Graves' disease, with or without GO, compared with healthy subjects and patients with autoimmune thyroiditis in a cross-sectional investigation.
- Conditions
- Graves Ophthalmopathy, Graves Disease, Autoimmune Thyroiditis
- Trial name
- IGF1RAbsGO (NCT03498417)
- Testing
- Serum antibodies against the IGF-1R
- Where
- Italy
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Thyroid Associated Ophthalmopathies
MHB018A Treatment in Patients With Active Thyroid Eye Disease
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants…
- Trial name
- NCT06989918
- Testing
- MHB018A
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves' Disease
An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease
To study the long-term safety and tolerability of BHV-1300
- Trial name
- NCT07901244
- Testing
- BHV-1300
- Volunteers
- 356 people
- Sponsor
- Biohaven Therapeutics Ltd.
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Graves' Dysthyroid Ophthalmopathy, Thyroid Related Orbitopathy
Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
This study is designed to treat patients with Graves' disease with Rituximab in an attempt to prevent or reverse the physically deforming and debilitating consequences of this disease.
- Trial name
- NCT00424151
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Silkiss, Rona Z., M.D., FACS
Graves Disease
Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients
Iodine therapy is the best treatment for graves disease.Most patients receive methimozale prior to radio-iodine treatment. This may decrease treatment response to iodine therapy.
- Trial name
- NCT01560299
- Testing
- Methimazole
- Where
- Iran
- Volunteers
- 150 people
- Sponsor
- Mashhad University of Medical Sciences
Thyroid Eye Disease
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease.
- Trial name
- NCT05795621
- Testing
- IBI311
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Graves Disease (Basedow's Disease)
Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance
The aim of our study is to compare in a randomized multicentric study the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation (experimental arm) compared to a conventional approach based on the…
- Trial name
- NCT01295333
- Testing
- the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation, The initiation of LT4 as soon as the first biological signs of hypothyroidism.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Thyroid Eye Disease
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R).
- Trial name
- OLE (NCT06179875)
- Testing
- Veligrotug
- Where
- 45 sites in United States, France and 6 more
- Volunteers
- 139 people
- Sponsor
- Viridian Therapeutics, Inc.